Genexine

At a glance

Genexine filed 32 disclosures in the last 12 months, including 2 issuance. The most recent key filing was on Oct 26.

Revenue for 2025 was ₩4.6B, up 56% on 2024. It made an operating loss of ₩36.2B. Debt was 50% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.4B and operating loss of ₩19.5B.

The 2025 annual report lists 68 employees with an average tenure of 5.8 years and average pay of ₩82.7M, #323 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩130M each on average. It paid no cash dividend for 2025. (주)한독 and related parties held 13.28% at year end.

From the 2025 annual report

Staff: 68 (20 men, 48 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩5.6B. Directors and auditors: 6, paid ₩778M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)한독 holds 13.28%; with 0 related parties the group holds 13.28% of common shares at year end.

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary